When xanthine based DPP - 4 inhibitors are compared with sitagliptin and vildagliptin it has shown a superior profile .
The first patents describing xanthines ( Figure 10 ) as DPP - 4 inhibitors came from Boehringer - Ingelheim ( BI ) and Novo Nordisk .
When xanthine based DPP - 4 inhibitors are compared with sitagliptin and vildagliptin DPP - 4 has shown a superior profile .
The first patents describing xanthines ( Figure 10 ) as DPP - 4 inhibitors came from Boehringer - Ingelheim ( BI ) and Novo Nordisk .